Transgenic rats, created using a novel application of zinc finger nuclease (ZFN) technology, could aid the development of animal models of human diseases.
Transgenic rats, created using a novel application of zinc finger nuclease (ZFN) technology, could aid the development of animal models of human diseases. The technology enables the mutation of specific genes, which can be passed down heritably, according to the results of the study "Knockout Rats via Embryo Microinjection of Zinc Finger Nucleases", published in Science.
"Until now, rat geneticists lacked a viable technique for "knocking out", or mutating, specific genes to understand their function," Howard Jacob, Director of the Human and molecular Genetics Center at the Medical College of Wisconsin (WI, USA), explained in a statement.
The world’s first targeted knockout rat (left) was created using CompoZr zinc finger nuclease technology to knock-out the green fluorescent protein (GFP) gene in the GFP rat (right).Image Courtesy of Sigma-Aldrich Coporation and the Medical College of Wisconsin.
The breakthrough was made by scientists at the Medical College of Wisconsin, Sangamo Biosciences (CA, USA), Sigma-Aldrich (MO, USA), Open Monoclonal Technology (CA, USA) and INSERM (France). It is believed that the rats will aid understanding of physiology, endocrinology, neurology, metabolism, parasitology, growth and development, and cancer.
"We have invested our time and resources to develop the CompoZr platform because we see enormous potential in a technology that can precisely manipulate the genome of living organisms," David Smoller, President of Sigma-Aldrich's Research Biotech business unit, which markets ZFN technology through its CompoZr line, said in the statement. "We are proud to be part of the public–private collaboration developing the proof-of-concept for this technique, which we believe will become the standard for the creation of genetically engineered research animals."
www.mcw.eduwww.sangamo.comwww.sigmaaldrich.com http://openmonoclonaltechnology.com/index.html www.inserm.fr
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.